Treatment of neurocysticercosis: A review Tratamiento de la neurocisticercosis: Revisión critica
Author
dc.contributor.author
Nogales Gaete, Jorge
Author
dc.contributor.author
Arriagada R, Camilo
Author
dc.contributor.author
Salinas R, Rodrigo
Admission date
dc.date.accessioned
2019-03-11T12:51:19Z
Available date
dc.date.available
2019-03-11T12:51:19Z
Publication date
dc.date.issued
2006
Cita de ítem
dc.identifier.citation
Revista Medica de Chile, Volumen 134, Issue 6, 2018, Pages 789-796
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164184
Abstract
dc.description.abstract
Neurocysticercosis (NCC) is the most common parasitic disease of the central nervous system. Several drugs, such as drugs against tapeworms, praziquantel or albendazole associated to corticosteroids, have been tested for the treatment of this condition. Although some have claimed the reduction or involution of cystic or granulomatous lesions, there is no consensus about the efficacy of these treatments. The natural evolution of the disease is not clear and this hampers the assessment of treatment effects. Moreover, there are no good imaging or clinical indicators that can predict the progression or spontaneous resolution of lesions, specially at the meningeal or ventricular compartment. Therefore, evidence based medicine does not have a definitive answer about the treatment, neither of seizures, the most common manifestation of NCC, or the varied and complex meningeal and ventricular involvement. This review includes experts opinions to give the clinician some clues for decision making